Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 10/20 | 0.39 |
| ▸ | NOS3 | P29474 | 8/20 | 0.39 |
| ▸ | NOS1 | P29475 | 8/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22681209 | 0.81 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1CYP3A4CYP2D6TSHR | |
| SCHEMBL24649065 | 0.81 | NOS2 (0.33) | NOS2NOS3NOS1 | |
| SCHEMBL27300605 | 0.81 | NOS2 (0.34) | NOS2NOS3NOS1HSP90AA1HSP90AB1 | |
| SCHEMBL24070968 | 0.78 | NOS3 (0.35) | NOS2NOS3NOS1HRH4 | |
| SCHEMBL21733973 | 0.77 | NOS2 (0.40) | NOS2NOS3NOS1HSP90AA1HSP90AB1 | |
| SCHEMBL24756842 | 0.77 | HSP90AA1 (0.38) | NOS2NOS3NOS1HSP90AA1HSP90AB1 | |
| SCHEMBL24649076 | 0.77 | NOS3 (0.32) | NOS2NOS3NOS1 | |
| SCHEMBL24854516 | 0.76 | NOS3 (0.35) | NOS2NOS3CYP3A4CYP2D6TSHR | |
| SCHEMBL25827014 | 0.76 | NOS3 (0.38) | NOS2NOS3NOS1CYP3A4CYP2D6 | |
| SCHEMBL27051415 | 0.76 | NOS2 (0.42) | NOS2NOS3NOS1BACE1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| WO-2023240189-A1 | TETRAHYDROPYRIDO 3,4-D PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230026856-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| WO-2023274324-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-01-05 | — | — | WO | disclosed |
| US-20220281893-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2022135470-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | 上海科州药物研发有限公司 | 2022-06-30 | — | — | WO | disclosed |
| US-11236068-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| WO-2021219090-A1 | QUINOXALINE DIONE DERIVATIVE AS IRREVERSIBLE INHIBITOR OF KRAS G12C MUTANT PROTEIN | 北京泰德制药股份有限公司 (CN) | 2021-11-04 | — | — | WO | disclosed |
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | ERASCA, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20210230142-A9 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-29 | — | — | US | disclosed |
| US-20200181118-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2020-06-11 | — | — | US | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | NOS2 4621/4885NOS3 4566/4885NOS1 4542/4885 |
| US-20210230142-A9 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | NOS2 3039/4885NOS3 3408/4885NOS1 3354/4885 |
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | SDHB, CCNI, SDHA | NOS2 562/4885NOS3 1553/4885NOS1 847/4885 |
| US-20220281893-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | OXA1L, CACNA1I, GRIK5 | NOS2 4718/4885NOS3 4712/4885NOS1 4805/4885 |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | NOS2 4592/4885NOS3 4696/4885NOS1 4756/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | NOS2 4639/4885NOS3 4599/4885NOS1 4548/4885 |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | NOS2 4484/4885NOS3 4437/4885NOS1 4465/4885 |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | AZI2, HDAC5, HDAC4 | NOS2 3912/4885NOS3 3905/4885NOS1 4313/4885 |
| US-20230026856-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | NOS2 4720/4885NOS3 4156/4885NOS1 4614/4885 |
| US-20200181118-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | NOS2 3039/4885NOS3 3408/4885NOS1 3354/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | NOS2 4765/4885NOS3 4762/4885NOS1 4692/4885 |
| US-11236068-B2 | Fused ring compounds | KRAS, NRAS, HRAS | NOS2 3039/4885NOS3 3408/4885NOS1 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.